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Background: The Hb levels of prospective blood donors are usually determined using a 
finger prick test. A new noninvasive Hb device has the advantage of not causing any sam-
pling pain. The purpose of this study was to evaluate the accuracy of the noninvasive Hb 
sensor and to compare its measurements with those of a currently used portable hemo-
globinometer.
Methods: Hb was measured using a noninvasive Hb sensor (NBM-200; OrSense, Israel), 
a portable hemoglobinometer (HemoCue; HemoCue AB, Sweden), and an automated he-
matology analyzer (LH500; Beckman Coulter, USA). The correlations between Hb mea-
surements taken by the NBM-200 and HemoCue with those by an automated hematology 
analyzer were assessed using intraclass correlation coefficients (ICCs). Hb measurements 
were compared among 3 different Hb level groups.
Results: The mean Hb values of 506 blood donors were 14.1 g/dL by the NBM-200, 14.0 
g/dL by the LH500, and 14.3 g/dL by the HemoCue. The correlation between the LH500 
and the NBM-200 was substantial (ICC=0.69), while that between the LH500 and the He-
moCue agreed almost perfectly (ICC=0.86). 
Conclusions: The possibility to judge to be eligible for donors who are ineligible to donate 
was substantial when using NBM-200. Even though the NBM-200 has the apparent ad-
vantage of noninvasiveness, its use in pre-screening should be given meticulous attention. 
Since pre-donation testing is crucial to protecting donors’ health, complete evaluation of 
the instrument should be performed prior to use.
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INTRODUCTION
Hb estimation is an integral part of donor screening to ensure 
donor safety and guarantee blood quality. The finger-stick CuSO4 
method has been the pre-donation screening method of choice 
for several decades. This method is widely used because it is 
fast, cost-effective, and easy to perform. However, quality control 
of the copper sulfate solution is difficult, and it presents prob-
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lems of biohazardous material disposal [1]. Even with strict qual-
ity control procedures in place, the CuSO4 method may fail to 
detect healthy donors or donors with abnormal protein levels 
and leukocytosis. The inaccuracy of the CuSO4 method has 
been continuously pointed out since it provides quantitative re-
sults and has a subjective endpoint [2-4]. Due to the unaccept-
able accuracy of the gravimetric CuSO4 method, it has increas-
ingly been replaced with more accurate point-of-care testing 
(POCT) devices that measure either Hb or hematocrit, such as 
the HemoCue (HemoCue AB, Angelholm, Sweden), Hemata-
STAT II (Separation Technology Inc., Altamonte Springs, FL, 
USA), and BeneCheck (General Life Biotechnology Co., Ltd, 
Taipei, Taiwan).
 The HemoCue, a portable hemoglobinometer that uses the 
dry chemistry principle, has been widely used to check Hb lev-
els in pre-donation screenings. The HemoCue has been avail-
able for several years and gives precise and accurate results 
when used on venous blood under laboratory conditions [5, 6]. 
The cost of using the HemoCue is comparatively higher than that 
of the CuSO4 method. Although the popularity of the HemoCue is 
increasing, reports regarding its accuracy are conflicting.
 The currently used methods that employ a copper sulfate so-
lution and a portable hemoglobinometer require donors to prick 
their fingers, which can cause pain. The finger prick is reported 
by blood donors as one of the worst parts of the blood donation 
process. Eliminating a major source of discomfort for donors may 
improve donor satisfaction and increase their willingness to do-
nate in the future.
 A newly released noninvasive Hb measurement instrument, 
the NBM-200 (OrSense, Nes Ziona, Israel), takes optical mea-
surements after temporary blood flow occlusion using a pneu-
matic finger cuff. Previous studies have validated the use of this 
noninvasive hemoglobinometer compared to multi-wavelength 
pulse CO-oximeters, but only in regards to patient care [5]. Lotfi 
et al. [7] reported that use of a noninvasive method of measur-
ing post-donation Hb to determine donor eligibility saved time 
and expenditure without endangering blood donors. To date, no 
study that has assessed the accuracy of the noninvasive NBM-
200 Hb sensor with regard to pre-donation screening, although 
its use has been described in other fields [8]. The objectives of 
the current study were to evaluate the accuracy of the NBM-200 
and to compare it with that of the currently used HemoCue in 
the measurement of Hb as part of the blood donor screening 
process.
 
METHODS
1. Subjects
The study was conducted at 2 blood donation sites, both of 
which were affiliated to Hanmaum Blood Center (Gwacheon, 
Korea). Blood donation volunteers who agreed to participate in 
this study were enrolled between April and September 2011. In-
formed consent was obtained from all of the participants. 
2. Study protocol and assay methods
Five-milliliter venous samples were collected in EDTA vacutain-
ers (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) 
and the Hb was tested using an LH500 automated hematology 
analyzer (Beckman Coulter, Inc., Brea, CA, USA) to determine 
the reference values. Capillary blood for the Hb measurements 
taken using the HemoCue was obtained from the finger at the 
same time the blood samples were taken for laboratory analysis. 
The noninvasive NBM-200 Hb sensor was placed on the donor’s 
thumb, and the Hb level was obtained within 1 min. The room 
temperature was kept at 18-26˚C, and its humidity was kept at 
30-70%.
 The volunteers’ systolic blood pressures were 90-180 mmHg, 
and their diastolic blood pressures were <100 mmHg. Three 
quality standard materials (low, normal, high) for the LH500 
were measured every day, and tests were done only when the 
Hb values of the standard materials were within 3 SD. Control 
cuvette was used to monitor HemoCue accuracy. Hb level was 
assessed when Hb values of the control cuvette were within±0.3 
g/dL of the assigned value.
 Hb measurements obtained using the NBM-200 and He-
moCue were compared with those obtained using the LH500. 
Using the LH500 values as a reference, the data were split into 
the following 3 groups since the eligibility criteria for an aphere-
sis donation is ≥12.0 g/dL and that for a whole blood donation 
is ≥12.5 g/dL. 
Group 1: Hb <12.0 g/dL
Group 2: Hb 12.0-12.4 g/dL
Group 3: Hb ≥12.5 g/dL
Hb measurements according to gender were compared among 
the 3 methods. 
This study protocol was approved by the institutional review 
board of the Hanmaum Blood Center.
3. Statistical analysis
Sensitivity and specificity were calculated as the percentage of 
ineligible donors who were correctly identified as ineligible to 
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donate blood and the percentage of eligible donors who were 
correctly identified as eligible to donate blood, respectively. The 
degree of homogeneity between the Hb measurements obtained 
using the 2 POCT devices (NBM-200, HemoCue) and the refer-
ence value obtained using the LH500 was evaluated by utilizing 
the intraclass correlation coefficient (ICC). Bland-Altman plots 
accommodating the double measurements within subjects were 
used to show the difference between the Hb measurements ob-
tained using the 2 POCT devices (NBM-200, HemoCue) along 
the y-axis vs. the Hb measurements obtained using the LH500 
along the x-axis with the 95% limits of agreement. 
 All statistical analyses were performed using SPSS Statistics 
18.0 (SPSS Inc., Chicago, IL, USA). The ICCs were interpreted 
as follows: <0, poor; 0.01-0.20, slight agreement; 0.21-0.40, fair 
agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substan-
tial agreement; and 0.81-1.00, almost perfect agreement [9].
RESULTS
Hb was measured in 506 donors (291 men, 215 women). The 
average Hb measurements were 14.0, 14.1, and 14.3 g/dL using 
the LH500, NBM-200, and HemoCue, respectively (Table 1). 
The Hb measurements of the LH500 had a normal distribution, 
while those of the NBM-200 were left-skewed and those of He-
moCue were slightly right-skewed (Fig. 1).
 A scatter plot of the NBM-200 vs. the LH500 showed wider 
distribution than that of the HemoCue vs. the LH500 (Fig. 2). 
The ICC between the LH500 and NBM-200 was 0.69, while that 
between the LH500 and the HemoCue was 0.86 (Table 1). A 
Bland-Altman plot showed that the 2 SD difference of Hb mea-
surements between the LH500 and the NBM-200 was >2.0 g/
dL, while that between the LH500 and the HemoCue was <2.0 
g/dL (Fig. 3).
 Comparison of Hb levels in the group of participants who 
were deemed ineligible to donate blood showed that the aver-
age Hb measurement obtained using the NBM-200 was 12.4 g/
dL, while that obtained using the HemoCue was 12.2 g/dL (Ta-
ble 1). The average Hb was 12.8 g/dL using the NBM-200 and 
12.9 g/dL using the HemoCue in the group of participants in 
whom the Hb values were 12.0-12.4 g/dL by the LH500 (those 
Table 1. Hemoglobin measurements and intraclass correlation coefficient (ICC) of subgroups according to whole blood donation and 
apheresis eligibility
Hemoglobin level (g/dL) N ICC (95% CI) Mean±SD Median (IQR) Minimum Maximum
NBM-200 Total 506 0.69 (0.64 to 0.73) 14.1±1.4 14.3 (13.2 to 15.2) 10.3 17.2
<  12.0 37 0.12 (-0.10 to -0.35) 12.4±1.2 12.5 (11.3 to 13.3) 10.3 14.7
12.0 to 12.4 18 0.03 (-0.23 to -0.34) 12.8±1.1 12.9 (12.3 to 13.5) 10.7 15.3
≥  12.5 451 0.61 (0.55 to 0.67) 14.4±1.2 14.5 (13.6 to 15.3) 10.3 17.2
HemoCue Total 506 0.86 (0.79 to 0.90) 14.3±1.4 14.2 (13.2 to 15.4) 10.3 17.7
<  12.0 17 0.32 (-0.10 to 0.64) 12.2±0.7 12.3 (11.9 to 12.6) 10.3 13.5
12.0 to 12.4 20 0.07 (-0.09 to 0.30) 12.9±0.6 12.7 (12.5 to 13.3) 12.1 14.5
≥  12.5 469 0.81 (0.76 to 0.85) 14.6±1.3 14.6 (13.5 to 15.6) 10.8 17.7
Abbreviations: CI, confidence interval; IQR, interquartile range.
Fig. 1. Histograms of the hemoglobin levels measured using the LH500 (A), the NBM-200 (B), and the HemoCue (C).
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who were eligible to donate plasma or platelets but not whole 
blood).
 Of the 70 donors who were deemed ineligible to donate blood 
by the LH500 (i.e., they had a Hb <12.5 g/dL), 43 donors 
(61.4%) were deemed eligible to donate whole blood by the 
NBM-200, while 39 donors (55.7%) were deemed eligible to do-
nate whole blood by the HemoCue (Table 2). Among the male 
donors who were deemed ineligible to donate blood by the 
LH500, 3 and 2 male donors were deemed eligible to donate by 
the NBM-200 and the HemoCue, respectively. Among female 
donors, 40 and 39 female donors were deemed eligible to do-
nate by the NBM-200 and the HemoCue, respectively. The num-
bers of donors who were eligible to donate whole blood among 
the donors who were initially deemed ineligible to donate any 
kind of blood were 23 and 16 by NBM-200 and HemoCue, re-
spectively.
 The sensitivities of the NBM-200 and HemoCue to ineligible 
donors were 33.3-42.7%, while their specificities to eligible do-
nors were 93.6-99.4% (Table 3).
DISCUSSION
In this study, we attempted to assess Hb estimation accuracy 
using a noninvasive Hb sensor and the currently used POCT 
device, the HemoCue, to test for anemia during the blood donor 
screening process. 
 The Hb measurements obtained using the NBM-200 showed 
a left-skewed distribution. The Hb measurements obtained us-
ing the NBM-200 also tended to be greater than those obtained 
using the LH500, which could be a threat to protection of do-
Fig. 2. Scatter plots of the hemoglobin levels measured using the LH500 vs. the NBM-200 (A) and the hemoglobin levels measured using 
the LH500 vs. the HemoCue (B).
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Fig. 3. Bland-Altman plot of the difference between the LH500 and the 2 point-of-care testing devices (A, NBM-200; B, HemoCue).
Abbreviation: AHA, automated hematology analzyer.
A
Di
ffe
re
nc
e b
et
we
en
 A
HA
 &
 N
BM
-2
00
4.00
2.00
0.00
-2.00
-4.00
 10.00 12.00 14.00 16.00 18.00
Average of AHA & NBM-200
+2 SD
Mean
-2 SD
B
Di
ffe
re
nc
e b
et
we
en
 A
HA
 &
 H
em
oC
ue
4.00
2.00
0.00
-2.00
 10.00 12.00 14.00 16.00 18.00
Average of AHA & HemoCue
+2 SD
Mean
-2 SD
Kim MJ, et al.
Noninvasive screening hemoglobinometer (NBM-200)
265http://dx.doi.org/10.3343/alm.2013.33.4.261 www.annlabmed.org
nors’ health. The findings imply that use of the NBM-200 as a 
pre-donation screening tool should occur only with meticulous 
caution.
 Sensitivity and specificity analyses showed that the NBM-200 
and HemoCue failed to detect more than half of the ineligible 
donors but allowed most eligible donors to donate blood.
 Analyses among subgroups showed that the subgroup ICCs 
were lower than the total group ICCs and that the smaller num-
ber of participants was attributed to the lower ICCs. The ICCs by 
the NBM-200 with LH500 implied substantial agreement, while 
those by the HemoCue with LH500 implied almost perfect agree-
ment. The ICCs by the NBM-200 were lower than those by the 
HemoCue in all subgroups.
 Analysis according to gender showed that female donors who 
were not eligible to donate blood were at greater risk of being 
falsely identified as eligible, which can create a substantial do-
nor safety risk. As such, the use of these POCT devices in the 
pre-donation screening process should occur meticulously with 
adequate measures (e.g., adjustment of Hb criteria level) to 
guarantee donor safety.
 Many researchers have reported no differences in the Hb 
measurements obtained using noninvasive Hb sensors versus 
automated hematology analyzers [8, 9]. However, our study 
showed only moderate agreement between Hb measurements 
obtained using the NBM-200 and those obtained using the 
LH500. Since Hb measurement inaccuracy might endanger a 
donor’s health, strict regulatory compliance should be used in 
the selection of pre-donation screening tools. In general, “strong 
agreement” is not adequate to ensure donors’ health since ac-
curate Hb estimation in blood donors is crucial to the prevention 
of adverse blood donation reactions and the exclusion of ineligi-
ble blood donors.
 The noninvasive Hb sensor mentioned here does not require 
venipuncture, is not affected by sampling error, and does not 
require the availability of highly skilled personnel. The measur-
ing system of the noninvasive Hb sensor comprises electronic 
circuitry, embedded software, and an attached finger sensor 
probe, and it automatically and continuously performs a self-test 
and calibration check during measurement sessions. The non-
invasive Hb sensor uses a validation process different from the 
Table 2. Number of participants by gender among the 3 hemoglobin estimation levels according to the NBM-200 and HemoCue point-of-
care testing systems
Reference values by group* N
NBM-200 HemoCue
<12.0 12.0-12.4 ≥12.5 <12.0 12.0-12.4 ≥12.5
Total 506 37 18 451 17 20 469
   Group 1 42 14 5 23 14 12 16
   Group 2 28 6 2 20 0 5 23
   Group 3 436 17 11 408 3 3 430
Male 291 1 0 290 0 3 288
   Group 1 2 1 0 1 0 2 0
   Group 2 2 0 0 2 0 0 2
   Group 3 287 0 0 287 0 1 286
Female 215 36 18 161 22 12 181
   Group 1 40 13 5 22 14 10 16
   Group 2 26 6 2 18 5 0 21
   Group 3 149 17 11 121 3 2 144
*Group 1: Hb <12.0 g/dL; Group 2: Hb 12.0-12.4 g/dL; Group 3: Hb ≥12.5 g/dL.
Table 3. Ineligibility sensitivity and eligibility specificity of the NBM-200 and HemoCue point-of-care testing systems in whole blood and 
apheresis donor selection
NBM-200 HemoCue
Whole blood Apheresis Whole blood Apheresis
Sensitivity (95% CI) 38.6 (28.1-50.3) 37.8 (24.1-53.9) 42.7 (31.6-54.5) 33.3 (21.0-48.5)
Specificity (95% CI) 93.6 (90.9-95.5) 94.0 (91.5-95.8) 98.6 (97.0-99.4) 99.4 (98.1-99.8)
Abbreviation: CI, confidence interval.
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conventional quality control materials of the automated hematol-
ogy analyzer and the control cuvette of the HemoCue. 
 Our result showed that the average Hb values obtained by the 
HemoCue hemoglobinometer were 0.3 g/dL higher than the ac-
tual Hb value. Similar results have been reported by other inves-
tigators [10-14]. However, the ICCs between the HemoCue and 
the LH500 showed almost perfect agreement in this study.
 The HemoCue can use capillary or venous blood in its Hb es-
timations. The Hb measurements of venous blood are reliable, 
but the accuracy and precision of capillary blood measurements 
are very much dependent on the technical skills of the person 
performing the procedure. The false deferral rate by the He-
moCue seems to be due to a lack of reliability when this method 
is used on capillary blood samples. 
 Many investigators have reported that capillary Hb values are 
higher than venous Hb values [13, 15]. Since the donor accep-
tance criteria described above were established using venous 
Hb measurements, the difference between capillary and venous 
hematological results must be kept in mind.
 The use of capillary samples for the diagnosis of anemia has 
been claimed to be inappropriate [16]. Capillary Hb is affected 
by the drop used (first, second, third, or fourth), exposure of cu-
vettes to moisture, and air bubbles that may occur within a cu-
vette [17]. Poor peripheral circulation, lack of cooperation, and 
instantaneous sedimentation of red cells in large drops of blood 
due to slow processing may all be associated with Hb measure-
ment inaccuracy in the use of capillary blood [18]. Another re-
port showed that pooling and mixing drops of skin puncture 
blood prior to analysis improved the Hb measurement precision 
of the HemoCue, but this is not feasible as a POCT device when 
using capillary blood [19]. If the Hb estimation results are higher 
than the actual values, a person with low Hb might be allowed 
to donate blood, which could both adversely affect the donor 
and hinder blood quality. 
 In the current study, we tried to minimize the sampling bias 
by allowing only trained staff to conduct the study and by limit-
ing the number of blood collection sites to 2. Despite these ef-
forts, the sampling bias may not have been completely elimi-
nated. Since the subjects were blood donor volunteers, the 
range of Hb values was not wide enough to make an accurate 
assessment. In addition, the Hb measurements of most of the 
volunteers were higher that the donor eligibility criteria. The abil-
ity to differentiate eligible and ineligible donors is critical in pro-
tecting donor health. The number of study subjects who were 
not eligible to make a donation was too small to show the obvi-
ous Hb estimation differences between the NBM-200 and the 
HemoCue.
 In summary, the results of this study imply that, if used very 
carefully, the NBM-200 can differentiate eligible and ineligible 
donors. Even though the NBM-200 eliminates the need for an 
invasive finger prick or venous blood draw, its use in donor pre-
screening should occur with meticulous attention. Hb measure-
ments by the HemoCue showed excellent agreement with those 
by the automated hematology analyzer. Since pre-donation test-
ing is crucial to protecting donors’ health, complete evaluation 
of an instrument should be performed prior to its use. Every ef-
fort should be made to improve the quality control of Hb mea-
surements to ensure donor safety and guarantee good blood 
quality.
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